Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
DexCom
DXCM
5
Workday
WDAY
US Stock MarketDetailed Quotes
HALO Halozyme Therapeutics
- 60.490
- +1.240+2.09%
Close Apr 25 16:00 ET
- 60.490
- 0.0000.00%
Post 20:01 ET
7.47BMarket Cap17.64P/E (TTM)
60.900High58.490Low992.97KVolume59.020Open59.250Pre Close59.75MTurnover0.81%Turnover Ratio17.64P/E (Static)123.53MShares66.00052wk High20.54P/B7.39BFloat Cap37.96552wk Low--Dividend TTM122.17MShs Float66.000Historical High--Div YieldTTM4.07%Amplitude1.410Historical Low60.168Avg Price1Lot Size
About Halozyme Therapeutics Company
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Company Profile
SymbolHALO
Company NameHalozyme Therapeutics
Listing DateNov 1, 2004
Founded1998
CEODr. Helen I. Torley, M.R.C.P.,MB.Ch.B.
MarketNASDAQ
Employees350
Fiscal Year Ends12-31
Address12390 El Camino Real
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92130
Phone1-858-794-8889
Websitehttp://www.halozyme.com
Company Executives
- Name
- Position
- Salary
- Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B.
- Director, President and Chief Executive Officer
- 12.74M
- Nicole LaBrosse
- Senior Vice President, Chief Financial Officer and Principal Accounting Officer
- 4.22M
- Mark Snyder
- Senior Vice President, General Counsel, Chief Compliance Officer and Secretary
- 8.67M
- Jeffrey W. Henderson
- Chairman of the Board
- 544.82K
- Connie L. Matsui
- Independent Director
- 460.04K
- Moni Miyashita
- Independent Director
- 455.04K
- Bernadette M. Connaughton
- Independent Director
- 470.04K
- Barbara G. Duncan
- Independent Director
- 485.26K
- Matthew L. Posard
- Independent Director
- 455.04K
- Dr. Mahesh Krishnan, M.B.A.
- Independent Director
- 437.51K
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now